Skip to main content
Premium Trial:

Request an Annual Quote

Protiva Ends Suit Against Merck Unit After Merck Licenses Protiva's RNAi Technology

NEW YORK (GenomeWeb News) — Merck has licensed RNAi technology from Protiva Biotherapeutics, and Protiva has agreed to drop ongoing litigation against the drug maker’s subsidiary Sirna Therapeutics, Protiva said this week.
 
Merck will use Protiva’s stable nucleic acid-lipid particles, or SNALP, technology in its pharmaceutical-development programs, Protiva said.
 
Terms of the non-exclusive license call for Protiva to receive a one-time payment in advance, and to be entitled to royalty payments if Merck markets any products stemming from the license.
 
Financial terms of the agreement were not disclosed.
 
The agreement to cease litigation includes an injunction against Sirna handed down by the Superior Court of California in March, Protiva said.

A comprehensive version of this article appears in the current issue of RNAi News, a GenomeWeb Daily News sister publication.

The Scan

Booster for At-Risk

The New York Times reports that the US Food and Drug Administration has authorized a third dose of the Pfizer-BioNTech SARS-CoV-2 vaccine for people over 65 or at increased risk.

Preprints OK to Mention Again

Nature News reports the Australian Research Council has changed its new policy and now allows preprints to be cited in grant applications.

Hundreds of Millions More to Share

The US plans to purchase and donate 500 million additional SARS-CoV-2 vaccine doses, according to the Washington Post.

Nature Papers Examine Molecular Program Differences Influencing Neural Cells, Population History of Polynesia

In Nature this week: changes in molecular program during embryonic development leads to different neural cell types, and more.